Premier Alternatives

Egenesis

Cambridge, MA · Founded 2015 · Privately Held (backing)

Developer of human-compatible engineered organs and cells designed to address the global shortage of transplantable organs. Egenesis is based in Cambridge, MA and was founded in 2015. Its last known valuation is $330 million. It has raised $454 million across 5 recorded rounds; the latest was a $25.4 million debt round in Feb 2024.

Last price · $/share
—
Implied valuation
$330.0M
Total raised
$454.0M
Last round
Debt
Feb 2024

Egenesis key facts

  • Developer of human-compatible engineered organs and cells designed to address the global shortage of transplantable organs.
  • Egenesis’s last known valuation is $330.0M.
  • It has raised $454.0M across 5 recorded rounds; the latest was Debt ($25.4M) in Feb 2024.
  • Notable investors include Khosla Ventures, Lux Capital, Alexandria Venture Investments, ARCH Venture Partners, Catalio Capital Management — 37 tracked in total.
  • Egenesis has filed 5 Form Ds with the SEC since 2016, most recently Feb 2024 ($25.4M sold to 11 investors).
  • Status: Privately Held (backing).
Free account
More of Egenesis with a free account
  • ·The complete investor list: 37 names
  • ·Watch Egenesis: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Egenesis funding rounds

5 rounds
Feb 2024Debt$25.4MSEC filing▮
Feb 2021Later Stage VC$125.0MSEC filing▮
Nov 2019Later Stage VC$100.0MSEC filing▮
Mar 2017Early Stage VC$12.6MSEC filing▮
Aug 2016Seed Round$2.0MSEC filing▮
Full funding history →

Egenesis valuation

Egenesis's last known valuation is $330 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.

How much has Egenesis raised?

Egenesis has raised $454 million across 5 recorded rounds since 2016. The largest was a $25.4 million debt round in Feb 2024.

Egenesis has filed 5 Form Ds with the SEC since 2016, most recently in Feb 2024 ($25.4 million sold to 11 investors).

Egenesis investors

37 investors are on record for Egenesis, including Khosla Ventures, Lux Capital, Alexandria Venture Investments and ARCH Venture Partners. By type, the record holds 11 venture capital firms and 3 hedge funds. The debt round in Feb 2024 drew 11 investors.

About Egenesis

Developer of human-compatible engineered organs and cells designed to address the global shortage of transplantable organs. The company offers a genome-engineering platform that inactivates porcine retroviruses, inserts human genes, and edits multiple immune-rejection pathways to transform solid organ and therapeutic cell transplantation for the treatment of life-threatening diseases, enabling patients with organ failure to access transplantable tissues and organs with improved compatibility and safety.

Sector
Healthcare
HQ
Cambridge, MA, United States
Founded
2015
Employees
135
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.

Valuation on record
$330.0M

Egenesis’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.